Current Studies

On a website of the US National Institutes of Health many ongoing clinical studies are listed. Please note that this list is not complete.

Here are some of the many current clinical studies.

THC / Dronabinol / Marinol
Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia at Hadassah Medical Organization, Jerusalem, Israel.
For more studies please click here.

Nabilone / Cesamet
Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis at University of Manitoba, Winnipeg, Canada.
For more studies please click here.

Nabiximols / Sativex
A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer in the United States, the UK and Germany.
For more studies please click here.

Cannabidiol (CBD)
Cannabidiol for Inflammatory Bowel Disease at Meir Medical Center, Kefar Saba, Israel.
For more studies please click here.

Smoked / Inhaled Cannabis
Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS at New York State Psychiatric Institute, USA.
Effects of Vaporized Marijuana on Neuropathic Pain at CTSC Clinical Research Center, Sacramento, United States.
For more studies please click here.

Contact

You are here: Home > British Association > Sativex

Sativex

Sativex, researched and developed by GW Pharmaceuticals, has now been approved in the UK. It has also been approved for use in Spain, Germany, Denmark, New Zealand and Canada.

Sativex oromucosal spray is available on the British National Health Service and, in some cases, is fully funded by the Primary Care Trust (PCT) local to the area a patient is in. The maximum a patient may have is one prescription per week. A prescription contains 3 x 10ml vials of Sativex.

Although currently used as an 'add-on' treatment, patients using Sativex are finding it to be a very effective, disease modifying medicine. If existing medicine is not effective or causing a patient to suffer unpleasant side effects, it may be to their advantage to request Sativex through their doctor or neurologist.

A patient may also find an advantage in providing their doctor or neurologist with the latest information as many PCTs are still referring to old reports. Accurate information can be obtained from the GW Pharmaceuticals website here.

IACM Conference 2013

7th Conference on Cannabinoids in Medicine

27-28 September 2013
Holiday Inn, Cologne, Germany.

More

European Workshop

6th European Workshop on Cannabinoids

18-20 April 2013
Trinity College Dublin, Ireland

Conference Website

Canada

The University of British Columbia in partnership with the ICRS and the CCIC will organize “Cannabinoids in Clinical Practice” on 21 June 2013, a full day continuing medical education (CME) event.
More